LAURALEE COLEMAN: Open Payments
NPI 1992715940 · SHELBYVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$871 in 49 payments from 13 companies in 2025. Trend: 2023 $799 · 2024 $927 · 2025 $871
Food & beverage: $871
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $250 |
| GlaxoSmithKline, LLC. | 6 | $110 |
| Novo Nordisk Inc | 6 | $105 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Lilly USA, LLC | 3 | $56 |
| PFIZER INC. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Amgen Inc. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
Products named: QULIPTA, TRELEGY ELLIPTA, VRAYLAR, NEXLETOL, VOQUEZNA, MOUNJARO, ELIQUIS, Wegovy.
Industry payments across KY — which companies pay providers there.
